2 Information about fluocinolone acetonide intravitreal implant

Information about fluocinolone acetonide intravitreal implant

Marketing authorisation indication

Fluocinolone acetonide intravitreal implant (Iluvien, Alimera Sciences) is indicated for 'prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye'.

Dosage in the marketing authorisation

Fluocinolone acetonide intravitreal implant is administered through intravitreal injection. Each implant contains 0.19 mg of fluocinolone acetonide and releases fluocinolone acetonide for up to 36 months.


£5,500 per implant (excluding VAT, British national formulary online [accessed May 2019]).

The company has a commercial arrangement. This makes fluocinolone acetonide intravitreal implant available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)